HealthFlex
×
  • About Us
    • Company Management
    • Meet Our Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
    • Careers
  • Technologies
    • Oncoprex® Delivery System
    • Reqorsa® Gene Therapy
    • GPX-002
  • Programs
    • Oncology
    • Diabetes
  • Clinical Trials
    • Pipeline
    • ONC-001
    • ONC-002
    • Acclaim-1
    • Acclaim-3
    • DIA-001 and DIA-002
    • Expanded Access Policy
  • Investors
    • Company Profile
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder FAQ
    • Downloads
    • Events
  • News
    • Press Releases
    • Blog Posts
    • Media Coverage
    • Videos
  • Contact

Genprex, Inc. Commences Initial Public Offering And Sets Price

October 13, 2017Press Releases

AUSTIN, Texas, Oct. 13, 2017 /PRNewswire/ — Genprex, Inc., (“Genprex”) a clinical stage gene therapy company, today announced that its initial public offering of a minimum of 2.5 million shares and a maximum of 4.5 million shares of its common stock has priced at $5.00 per share.

Genprex Logo

Genprex expects the offering to close on or about November 6, 2017, subject to completion of the minimum offering and other customary closing conditions, and that its shares will begin trading on the NASDAQ Capital Market under the symbol “GNPX” shortly after closing.

Genprex intends to use the net proceeds from this offering together with its existing cash resources for the following purposes:

  • Complete the ongoing Phase II clinical trial of the combination of Oncoprex with erlotinib;
  • Commence a Phase I/II clinical trial of Oncoprex in combination with an immunotherapy;
  • Conduct preclinical research, including biomarker studies;
  • Prepare filings with the FDA;
  • Working capital and general corporate purposes which may include funding new research and development activities, hiring additional personnel, capital expenditures and the costs of operating as a public company.

Network 1 Financial Securities, Inc. is acting as the underwriter for the offering.

Genprex’s registration statement relating to the offering has been filed with, and declared effective by, the United States Securities and Exchange Commission.  This press release does not constitute an offer to sell, or a solicitation of an offer to buy, the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

The offering of the securities is made only by means of a prospectus forming a part of the effective registration statement.  A copy of the prospectus relating to the offering may be obtained by contacting Network 1 Financial Securities, Inc., The Galleria, 2 Bridge Avenue, Building 2, Suite 241, Red Bank, NJ 07701, or by calling toll-free 1-800-886-7007, or by email to Alice McKeon at [email protected], or via the website at https://genprex.network1.com/.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Forward-Looking Statements

This press release contains forward-looking statements, including statements concerning Genprex’s proposed offering of securities.  Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward looking statements because they contain words such as “intends”, “may”, “will”, “should”, “expects”, “plans”, “anticipates”, “could”, “target”, “projects”, “contemplates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. The consummation of the proposed securities offering and the terms thereof are subject to numerous factors, many of which are beyond the control of Genprex, including, without limitation, market conditions, failure of closing conditions and risks and other matters set forth in the documents filed by Genprex with the Securities and Exchange Commission. You should not place undue reliance upon forward-looking statements as predictions of future events. Genprex has based the forward-looking statements contained in this press release on its current expectations and projections about future events and trends that it believes may affect its business, financial condition, results of operations and prospects. Genprex cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking statements. The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. Genprex undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contact:              

James Heins
ICR, Inc. 
203-682-8251
[email protected]

Stephanie Carrington
ICR, Inc.
646-277-1282
[email protected]

 

View original content with multimedia:http://www.prnewswire.com/news-releases/genprex-inc-commences-initial-public-offering-and-sets-price-300536729.html

SOURCE Genprex, Inc.


Note: When you click on media articles, a new page will open indicating that you are leaving the Genprex, Inc. website and entering a third-party website not affiliated with Genprex Inc. or any of its affiliates. No information contained in a linked site has been endorsed or approved by Genprex, Inc. and Genprex, Inc. is not responsible for the content of such third-party websites.

Categories

  • Acclaim 1
  • Acclaim 2
  • Acclaim 3
  • Blog Posts
  • Clinical Trials
  • Media Coverage
  • Press Releases

Recent Posts

  • Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes
  • Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma
  • Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting
  • Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
  • Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Archives

  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • November 2021
  • September 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • October 2017
  • July 2017
  • April 2017
  • March 2017
  • January 2017
  • December 2016
  • November 2016
  • August 2016
  • November 2015
  • September 2015
  • May 2014
  • April 2012
  • September 2011
  • July 2011
  • June 2011
  • April 2011
  • May 2010

Tag Cloud

AACR Acclaim-1 Acclaim-2 Acclaim-3 Aldevron ASCO Austin Business Journal Board of Directors cancer Clinical Trials conference Conferences Diabetes Events Fast Track Fast Track Designation FDA FDA Fast Track Fitness gene therapy Glioblastoma Health Immunotherapies Immunotherapy KOL Event Lung cancer Manufacturing Media Coverage Nonviral Delivery System Nonviral Vector NPRL2 NSCLC Oncology Oncoprex Preclinical Data Presentation Presentations Reqorsa Russell Index Shareholder Letter Tagrisso Tips TUSC2 Type 2 Video

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

(877) 774-GNPX (4679)

3300 Bee Cave Road, Suite 650-227 Austin, TX 78746

Quick Links

  • About Us
  • Clinical Trials
  • Investors
  • Downloads
  • Press Releases
  • X
  • Facebook
  • LinkedIn

Latest News

  • Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes May 7
  • Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma May 6
  • Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting Apr 30
  • Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting Apr 29
Designed and Secured by Barsec
Copyright ©2025 all rights reserved.
Home - Privacy Policy - Terms of Use